A new drug cannot be sold until it is tested in people. That testing is a clinical trial. It is a research study designed to answer whether a treatment is safe and effective. Clinical trials are conducted in phases. Phase I tests safety in a small number of healthy volunteers or patients. Phase II tests efficacy and side effects in a larger group. Phase III tests the treatment against the standard of care in hundreds or thousands of patients. Phase IV continues monitoring after approval.

Trials are expensive and risky. A single Phase III trial can cost hundreds of millions of dollars and take years. Most drugs that enter clinical testing fail. The failure rate is over 90 percent. The reasons vary: the drug does not work, it causes unacceptable side effects, or it is no better than existing treatments.

Trials are also ethical minefields. Participants must give informed consent. They must understand the risks and the alternatives. They must not be coerced or exploited. Vulnerable populations, like prisoners, children, and the cognitively impaired, receive special protections. Institutional review boards oversee the protocols. Data must be reported honestly, even when the results are negative.

Clinical trials are the bridge between the lab and the clinic. Without them, medicine would be guesswork. With them, it is evidence-based.